Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
04:01pm, Thursday, 07'th May 2026
PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on
BridgeBio to Participate in May and June Investor Conferences
04:01pm, Wednesday, 06'th May 2026
PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for geneti
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
07:30am, Wednesday, 06'th May 2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
07:30am, Tuesday, 05'th May 2026
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for geneti
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
07:30am, Monday, 04'th May 2026
PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for geneti
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
07:30am, Thursday, 30'th Apr 2026
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for gene
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore
05:58pm, Wednesday, 29'th Apr 2026
BridgeBio remains a compelling Buy, driven by Attruby's strong U.S. launch and favorable competitive dynamics following Pfizer's patent settlements. Attruby's peak annual sales are conservatively mode
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Wednesday, 29'th Apr 2026
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
11:09am, Tuesday, 28'th Apr 2026
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
B. Metzler seel. Sohn & Co. AG Cuts Position in BridgeBio Pharma, Inc. $BBIO
03:46am, Monday, 27'th Apr 2026
B. Metzler seel. Sohn and Co. AG reduced its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 29.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and
BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy
11:50am, Thursday, 23'rd Apr 2026
BridgeBio Pharma, Inc. has surged 130% since last year, now trading at a $14.4bn market cap, driven by optimism around its pipeline and ATTR-CM drug Attruby. Attruby posted $362m in 2025 sales but fac
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Wednesday, 22'nd Apr 2026
PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for gene
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO
03:32am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. trimmed its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 87.1% during the fourth quarter, according to the company in its most recent filing with the Securities
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
03:30pm, Monday, 30'th Mar 2026
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
07:30am, Monday, 30'th Mar 2026
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically
